Published on Friday April 05, 2024

Smooth Drug Development March 2024 News Release

We are working on the following new projects:

  • We received a contract for a phase I study with Pembrolizumab.
  • We are signing a contract for a bioequivalence study with patients in oncology.
  • A contract for medical writing services with Efmoroctocog alpha was signed.
  • Smooth was awarded with two projects for medical writing for bioequivalence studies with Tyloron and Fabomotisol.
  • Smooth is awarded with a phase II trial in flu.

We are happy to reach the following milestones in our projects:

  • 22 patients were randomized in a phase III clinical trial in paroxysmal nocturnal hemoglobinuria.
  • The CSR report was prepared in the trial in adhesions during surgeries.
  • Start-up was performed in the phase II trial in flu.
  • Start-up was performed in the Thiocolchicoside trial.